REGN Finds Redemption After Impressive Earnings Report

Sales of REGN's Covid-19 antibody cocktail beat expectations

Deputy Editor
May 6, 2021 at 10:40 AM
facebook twitter linkedin

The shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) are rising on the company's upbeat first-quarter earnings report, which boasted a rise in profits to $9.89 per share -- toppling analysts' estimates. The pharma firm's sales of its SARS-CoV-2 antibody cocktail REGEN-COV also beat analysts' forecasts. The stock was last seen up 1.9% to trade at $491.76. 

It's been a hard run for REGN on the charts, however. Still, the security's year-to-date breakeven may hold out as support for its recent drop, paired with the 80-day moving average. In fact, it looks like a familiar rejection level at the 140-day moving average may be partly to blame for the security's latest pullback. This trendline was also responsible for two other dramatic selloffs since November. 

REGN's underperformance has helped drive plenty of option bears to the equity. At the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the security sports a 10-day put/call volume ratio of 1.23, which stands higher than 91% of readings from the past year.  

Analysts, meanwhile, have taken a slightly more optimistic stance, with nine calling the stock a "strong buy," compared to six "hold" ratings. Plus, the 12-month consensus price target of $633.82 is a 29.1% premium to current levels. 

Grab your FREE Eternal Contrarian report!


Special Offers from Schaeffer's Trading Partners